EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Structural Immunology of SARS ‐ CoV ‐2

Meng Yuan, Ian A Wilson iD

Immunological Reviews · 2025-01 · 329 (1)

DOI: 10.1111/imr.13431 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 27.12.2024. Verfasst von Meng Yuan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, COVID-19, Antibodies, Viral. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS‐CoV‐2 spike (S) protein has undergone significant evolution, enhancing both receptor binding and immune evasion. In this review, we summarize ongoing efforts to develop antibodies targeting various epitopes of the S protein, focusing on their neutralization potency, breadth, and escape mechanisms. Antibodies targeting the receptor‐binding site (RBS) typically exhibit high neutralizing potency but are frequently evaded by mutations in SARS‐CoV‐2 variants. In contrast, antibodies targeting conserved regions, such as the S2 stem helix and fusion peptide, exhibit broader reactivity but generally lower neutralization potency. However, several broadly neutralizing antibodies have demonstrated exceptional efficacy against emerging variants, including the latest omicron subvariants, underscoring the potential of targeting vulnerable sites such as RBS‐A and RBS‐D/CR3022. We also highlight public classes of antibodies targeting different sites on the S protein. The vulnerable sites targeted by public antibodies present opportunities for germline‐targeting vaccine strategies. Overall, developing escape‐resistant, potent antibodies and broadly effective vaccines remains crucial for combating future variants. This review emphasizes the importance of identifying key epitopes and utilizing antibody affinity maturation to inform future therapeutic and vaccine design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19Antibodies, ViralHumansAntibodies, NeutralizingImmune EvasionCOVID-19 VaccinesAnimalsEpitopes

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2neutralizing antibodyspikevaccineviral evolution

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, Neutralizingspike protein, SARS-CoV-2Antibodies, ViralCOVID-19 VaccinesEpitopes

Autor:innen und Institutionen

  • Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
  • The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.

ORCID-Profile: Ian A Wilson

Förderung

  • Gates Foundation
  • Bill and Melinda Gates Foundation

Zitieren

APA

Yuan, M., & Wilson, I. A. (2025). Structural Immunology of SARS ‐ CoV ‐2. Immunological Reviews, 329(1). https://doi.org/10.1111/imr.13431

Vancouver

Yuan M, Wilson IA. Structural Immunology of SARS ‐ CoV ‐2. Immunological Reviews. 2025;329(1). doi:10.1111/imr.13431

BibTeX
@article{Yuan2025,
  author = {Yuan, Meng and Wilson, Ian A},
  title = {Structural Immunology of SARS ‐ CoV ‐2},
  journal = {Immunological Reviews},
  year = {2025},
  volume = {329},
  number = {1},
  doi = {10.1111/imr.13431}
}
Kostenlos starten →